AIDS-associated NHL (A-NHL) is one of the most common
AIDS-associated malignancies. Like NHL in the general population, A-NHL exhibits a highly variable profile in clinical and histologic characteristics, with B-cell lymphoma, especially diffuse large B-cell lymphoma, as the most frequent subtype, accounting for more than 90% of all A-NHL cases.5,6 NHL as the primary manifestation of AIDS is encountered less frequently in oncologic practice.
(1-5) The aetiopathogenesis of HIV-related anaemia is complex and multifactorial, including HIV itself, co-morbid opportunistic infections,
AIDS-associated malignancies, drugs, haemolysis, malnutrition, malabsorption or myelodysplasia.
Research on
AIDS-associated malignancies has focused on the interplay of immunity and viral infections and has increased our understanding of cancer pathogenesis.
The AIDS Malignancy Consortium (AMC) is a National Cancer Institute (NCI)-supported clinical trials group, founded in 1995 to support innovative trials for
AIDS-associated malignancies. The AMC is composed of 15 main Clinical Trials Sites and their affiliates, and an Operations and Statistical Center.
Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL) are the two most prominent
AIDS-associated malignancies. Earlier in the AIDS epidemic, the incidence of both cancers had been increasing.